<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460263</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Population-Based Study of SARS-CoV-2 IgG Antibody Responses to Vaccination in Manitoba.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1095</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101095</ELocationID><Abstract><AbstractText>Understanding variables that influence antibody responses to COVID-19 vaccination within a population can provide valuable information on future vaccination strategies. In this population-based study, we examined the antibody responses to COVID-19 vaccination in Manitoba using residual serum specimens collected between January 2021 and March 2022 (n = 20,365). Samples were tested for spike and nucleocapsid IgG against SARS-CoV-2 using clinically validated assays. We assessed the impacts of multiple factors on post-vaccination antibody titres including type of vaccine, age, sex, geographic location, number of doses received, and timing of vaccination. Our investigation demonstrated that vaccination with one dose of Moderna mRNA-1273 elicited higher anti-spike IgG titres overall compared to Pfizer BNT162b2 vaccination, while one dose of Pfizer BNT162b2 followed by a second dose of Moderna mRNA-1273 exhibited higher titres than two doses of Pfizer BNT162b2 or Moderna mRNA-1273, irrespective of age. Age and time post-vaccination had considerable effects on antibody responses, with older age groups exhibiting lower anti-spike IgG titres than younger ages, and titres of those vaccinated with Pfizer BNT162b2 waning faster than those vaccinated with Moderna mRNA-1273 or a combination of Pfizer BNT162b2 and Moderna mRNA-1273. Antibody titres did not appear to be affected by sex or geographic location. Our results identify how factors such as age and type of vaccine can influence antibody responses to vaccination, and how antibody titres wane over time. This information highlights the importance of tailoring vaccine regimens to specific populations, especially those at increased risk of severe COVID-19 and can be used to inform future vaccination strategies, scheduling of booster doses, and public health measures.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Brielle</ForeName><Initials>B</Initials><Identifier Source="ORCID">0009-0005-8862-4989</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Caeseele</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3A 1S1, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cadham Provincial Laboratory, Winnipeg, MB R3E 3J7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bullard</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cadham Provincial Laboratory, Winnipeg, MB R3E 3J7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeppky</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Epidemiology &amp; Surveillance, Manitoba Health, Seniors and Active Living, Winnipeg, MB R3B 3M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yichun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Epidemiology &amp; Surveillance, Manitoba Health, Seniors and Active Living, Winnipeg, MB R3B 3M9, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reimer</LastName><ForeName>Joss</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Winnipeg Regional Health Authority, Winnipeg, MB R3B 1E2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinnon</LastName><ForeName>Lyle R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban 4001, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology, University of Nairobi, Nairobi P.O. Box 19676 00202, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Souradet Y</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0002-0982-1302</Identifier><AffiliationInfo><Affiliation>Department of Community Health Sciences, University of Manitoba, Winnipeg, MB R3E 0W2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kindrachuk</LastName><ForeName>Jason</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3305-7084</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Manitoba, Winnipeg, MB R3E 0W2, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manitoba Centre for Proteomics and Systems Biology, Health Science Centre, Winnipeg, Manitoba R3E 3P4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Derek R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology &amp; Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cadham Provincial Laboratory, Winnipeg, MB R3E 3J7, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089-SS</GrantID><Agency>Canadian COVID-19 Immunity Task Force</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgG</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">serology</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460263</ArticleId><ArticleId IdType="pmc">PMC11511381</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101095</ArticleId><ArticleId IdType="pii">vaccines12101095</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 24 July 2023)].  Available online:  https://covid19.who.int.</Citation></Reference><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modelling Study. Lancet Infect. Dis. 2022;22:1293–1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan S.A., Chung H., Brown K.A., Austin P.C., Fell D.B., Gubbay J.B., Nasreen S., Schwartz K.L., Sundaram M.E., Tadrous M., et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw. Open. 2022;5:e2232760. doi: 10.1001/jamanetworkopen.2022.32760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.32760</ArticleId><ArticleId IdType="pmc">PMC9500552</ArticleId><ArticleId IdType="pubmed">36136332</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention Science Brief: COVID-19 Vaccines and Vaccination.  [(accessed on 17 July 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009769</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine-Tiefenbrun M., Yelin I., Alapi H., Katz R., Herzel E., Kuint J., Chodick G., Gazit S., Patalon T., Kishony R. Viral Loads of Delta-Variant SARS-CoV-2 Breakthrough Infections after Vaccination and Booster with BNT162b2. Nat. Med. 2021;27:2108–2110. doi: 10.1038/s41591-021-01575-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01575-4</ArticleId><ArticleId IdType="pubmed">34728830</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P., Kemp S.A., Dhar M.S., Papa G., Meng B., Ferreira I.A.T.M., Datir R., Collier D.A., Albecka A., Singh S., et al. SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion. Nature. 2021;599:114–119. doi: 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Accorsi E.K., Britton A., Fleming-Dutra K.E., Smith Z.R., Shang N., Derado G., Miller J., Schrag S.J., Verani J.R. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327:639–651. doi: 10.1001/jama.2022.0470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.0470</ArticleId><ArticleId IdType="pmc">PMC8848203</ArticleId><ArticleId IdType="pubmed">35060999</ArticleId></ArticleIdList></Reference><Reference><Citation>Meister T., Kolde A., Fischer K., Pisarev H., Kolde R., Kalda R., Suija K., Tisler A., Uusküla A. A Retrospective Cohort Study of Incidence and Risk Factors for Severe SARS-CoV-2 Breakthrough Infection among Fully Vaccinated People. Sci. Rep. 2023;13:8531. doi: 10.1038/s41598-023-35591-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-35591-w</ArticleId><ArticleId IdType="pmc">PMC10213588</ArticleId><ArticleId IdType="pubmed">37237050</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention COVID-19 Vaccine Effectiveness Update.  [(accessed on 17 July 2023)]; Available online:  https://covid.cdc.gov/covid-data-tracker/#vaccine-effectiveness.</Citation></Reference><Reference><Citation>Health Canada Health Canada Authorizes First COVID-19 Vaccine.  [(accessed on 23 November 2023)].  Available online:  https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-first-covid-19-vaccine0.html.</Citation></Reference><Reference><Citation>Health Canada Health Canada Authorizes Moderna COVID-19 Vaccine.  [(accessed on 24 November 2023)].  Available online:  https://www.canada.ca/en/health-canada/news/2020/12/health-canada-authorizes-moderna-covid-19-vaccine.html.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|COVID-19 Vaccine Bulletin #1.  [(accessed on 13 October 2023)]; Available online:  https://news.gov.mb.ca/news/?archive=&amp;item=50057.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|COVID-19 Vaccine Bulletin #44.  [(accessed on 27 November 2023)]; Available online:  https://news.gov.mb.ca/news/index.html?item=50883&amp;posted=2021-02-26.</Citation></Reference><Reference><Citation>Coronavirus Vaccination Now Open to Manitobans 95 and over, First Nations 75 and over—Winnipeg|Globalnews.Ca.  [(accessed on 27 November 2023)].  Available online:  https://globalnews.ca/news/7659967/coronavirus-manitoba-vaccination-plan-general-population/</Citation></Reference><Reference><Citation>Public Health Agency of Canada COVID-19 Vaccination: Vaccination Coverage.  [(accessed on 24 July 2023)].  Available online:  https://health-infobase.canada.ca/covid-19/vaccination-coverage/#a3.</Citation></Reference><Reference><Citation>Canada P.H.A. of Demographics: COVID-19 Vaccination Coverage in Canada—Canada.Ca.  [(accessed on 14 December 2023)].  Available online:  https://health-infobase.canada.ca/covid-19/vaccination-coverage/archive/2023-09-11/#a5.</Citation></Reference><Reference><Citation>Public Health Agency of Canada COVID-19 Vaccination Technical Notes—Canada.Ca.  [(accessed on 28 March 2024)].  Available online:  https://health-infobase.canada.ca/covid-19/vaccination-coverage/technical-notes.html#a5.</Citation></Reference><Reference><Citation>Duong S., Burtniak J., Gretchen A., Mai A., Klassen P., Wei Y., Loeppky C., Shaw S.Y., Bullard J., Van Caeseele P., et al. Riding High: Seroprevalence of SARS-CoV-2 after 4 Pandemic Waves in Manitoba, Canada, April 2020–February 2022. BMC Public Health. 2023;23:2420. doi: 10.1186/s12889-023-17239-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-023-17239-6</ArticleId><ArticleId IdType="pmc">PMC10696886</ArticleId><ArticleId IdType="pubmed">38053033</ArticleId></ArticleIdList></Reference><Reference><Citation>DiaSorin LIASON SARS-CoV-2 S1/S2 IgG ([REF] 311460) 2021.  [(accessed on 22 March 2024)]; Available online:  https://www.fda.gov/media/137359/download.</Citation></Reference><Reference><Citation>Abbott SARS-CoV-2 IgG—For Use with Architect 2022.  [(accessed on 22 March 2024)]; Available online:  https://www.fda.gov/media/137383/download.</Citation></Reference><Reference><Citation>Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer; New York, NY, USA: 2016.</Citation></Reference><Reference><Citation>van den Brand T. Ggh4x: Hacks for “Ggplot2”. 2023.  [(accessed on 30 November 2023)].  Available online:  https://teunbrand.github.io/ggh4x/index.html.</Citation></Reference><Reference><Citation>Clarke E., Sherrill-Mix S., Dawson C. Ggbeeswarm: Categorical Scatter (Violin Point) Plots 2023.  [(accessed on 30 November 2023)].  Available online:  https://cran.r-project.org/web/packages/ggbeeswarm/index.html.</Citation></Reference><Reference><Citation>Sjoberg D.D., Whiting K., Curry M., Lavery J.A., Larmarange J. Reproducible Summary Tables with the Gtsummary Package. R J. 2021;13:570–580. doi: 10.32614/RJ-2021-053.</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/RJ-2021-053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenth R.V., Bolker B., Buerkner P., Giné-Vázquez I., Herve M., Jung M., Love J., Miguez F., Riebl H., Singmann H. Emmeans: Estimated Marginal Means, Aka Least-Squares Means. 2024.  [(accessed on 30 November 2023)].  Available online:  https://cran.r-project.org/web/packages/emmeans/index.html.</Citation></Reference><Reference><Citation>Kassambara A. Rstatix: Pipe-Friendly Framework for Basic Statistical Tests. 2023.  [(accessed on 30 November 2023)].  Available online:  https://rpkgs.datanovia.com/rstatix/</Citation></Reference><Reference><Citation>R Core Team R: A Language and Environment for Statistical Computing 2023.  [(accessed on 30 November 2023)].  Available online:  https://www.R-project.org.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|Manitoba Opens First COVID-19 Immunization Clinic.  [(accessed on 17 January 2024)]; Available online:  https://news.gov.mb.ca/news/index.html?item=50068&amp;posted=2020-12-16.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|COVID-19 Vaccine Bulletin #77.  [(accessed on 27 November 2023)]; Available online:  https://news.gov.mb.ca/news/index.html?item=51254&amp;posted=2021-05-12.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|Province Begins Booking COVID-19 Immunization Appointments to Protect First Priority Group.  [(accessed on 13 October 2023)]; Available online:  https://news.gov.mb.ca/news/?archive=&amp;item=50022.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|COVID-19 Vaccine Bulletin #47.  [(accessed on 27 November 2023)]; Available online:  https://news.gov.mb.ca/news/index.html?item=50922&amp;posted=2021-03-05.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|COVID-19 Vaccine Bulletin #96.  [(accessed on 27 November 2023)]; Available online:  https://news.gov.mb.ca/news/index.html?item=51496&amp;posted=2021-06-25.</Citation></Reference><Reference><Citation>Province of Manitoba|News Releases|COVID-19 Vaccine Bulletin #139.  [(accessed on 27 November 2023)]; Available online:  https://news.gov.mb.ca/news/index.html?item=52729&amp;posted=2021-11-15.</Citation></Reference><Reference><Citation>Manitoba Government [@MBGov] Manitobans 18+ Can Now Get Their #COVID19Vaccine Booster Dose Sooner: 4 Months after Being Fully Vaccinated or after Receiving Their 1st Booster Dose. Twitter 2022.  [(accessed on 17 January 2024)]; Available online:  https://x.com/MBGov/status/1527763596075094016.</Citation></Reference><Reference><Citation>Montoya J.G., Adams A.E., Bonetti V., Deng S., Link N.A., Pertsch S., Olson K., Li M., Dillon E.C., Frosch D.L. Differences in IgG Antibody Responses Following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines. Microbiol. Spectr. 2021;9:e01162-21. doi: 10.1128/Spectrum.01162-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.01162-21</ArticleId><ArticleId IdType="pmc">PMC8579939</ArticleId><ArticleId IdType="pubmed">34756093</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensels D., Pierlet N., Penders J., Mesotten D., Heylen L. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA. 2021;326:1533–1535. doi: 10.1001/jama.2021.15125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15125</ArticleId><ArticleId IdType="pmc">PMC8406205</ArticleId><ArticleId IdType="pubmed">34459863</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart A.S.V., Shaw R.H., Liu X., Greenland M., Aley P.K., Andrews N.J., Cameron J.C., Charlton S., Clutterbuck E.A., Collins A.M., et al. Immunogenicity, Safety, and Reactogenicity of Heterologous COVID-19 Primary Vaccination Incorporating mRNA, Viral-Vector, and Protein-Adjuvant Vaccines in the UK (Com-COV2): A Single-Blind, Randomised, Phase 2, Non-Inferiority Trial. Lancet Lond. Engl. 2022;399:36–49. doi: 10.1016/S0140-6736(21)02718-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02718-5</ArticleId><ArticleId IdType="pmc">PMC8648333</ArticleId><ArticleId IdType="pubmed">34883053</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanagan K.L., Fink A.L., Plebanski M., Klein S.L. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu. Rev. Cell Dev. Biol. 2017;33:577–599. doi: 10.1146/annurev-cellbio-100616-060718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-100616-060718</ArticleId><ArticleId IdType="pubmed">28992436</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellini R., Venuti A., Pimpinelli F., Abril E., Blandino G., Campo F., Conti L., De Virgilio A., De Marco F., Di Domenico E.G., et al. Initial Observations on Age, Gender, BMI and Hypertension in Antibody Responses to SARS-CoV-2 BNT162b2 Vaccine. EClinicalMedicine. 2021;36 doi: 10.1016/j.eclinm.2021.100928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100928</ArticleId><ArticleId IdType="pmc">PMC8177433</ArticleId><ArticleId IdType="pubmed">34109307</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes M.D.C.R., Vasconcelos G.S., de Melo A.C.L., Matsui T.C., Caetano L.F., de Carvalho Araújo F.M., Fonseca M.H.G. Influence of Age, Gender, Previous SARS-CoV-2 Infection, and Pre-Existing Diseases in Antibody Response after COVID-19 Vaccination: A Review. Mol. Immunol. 2023;156:148–155. doi: 10.1016/j.molimm.2023.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2023.03.007</ArticleId><ArticleId IdType="pmc">PMC9998295</ArticleId><ArticleId IdType="pubmed">36921489</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevisan C., Raparelli V., Malara A., Abbatecola A.M., Noale M., Palmieri A., Fedele G., Di Lonardo A., Leone P., Schiavoni I., et al. Sex Differences in the Efficacy and Safety of SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: Insights from the GeroCovid Vax Study. Intern. Emerg. Med. 2023;18:1337–1347. doi: 10.1007/s11739-023-03283-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-023-03283-y</ArticleId><ArticleId IdType="pmc">PMC10148701</ArticleId><ArticleId IdType="pubmed">37120663</ArticleId></ArticleIdList></Reference><Reference><Citation>Northern Health Region . Northern Health Region Community Health Assessment 2019. Northern Health Region; Flin Flon, MB, Canada: 2019.</Citation></Reference><Reference><Citation>Southern Health-Santé Sud . Southern Health-Santé Sud Community Health Assessment 2019. Southern Health-Santé Sud; Southport, MB, Canada: 2019.</Citation></Reference><Reference><Citation>Southern Health-Santé Sud . Southern Health-Santé Sud (SH-SS) 2019 Community Health Assessment Winkler District. Southern Health-Santé Sud; Southport, MB, Canada: 2019.</Citation></Reference><Reference><Citation>Southern Health-Santé Sud . Southern Health-Santé Sud (SH-SS) 2019 Community Health Assessment Stanley District. Southern Health-Santé Sud; Southport, MB, Canada: 2019.</Citation></Reference><Reference><Citation>Froese I. This Manitoba Community Has a Vaccination Rate of 24% against COVID-19. Here’s Why. CBC News. Sep 29, 2021.</Citation></Reference><Reference><Citation>CTV News Winnipeg INTERACTIVE MAP: COVID-19 Vaccine Uptake in Manitoba.  [(accessed on 29 May 2024)].  Available online:  https://winnipeg.ctvnews.ca/interactive-map-covid-19-vaccine-uptake-in-manitoba-1.5465089.</Citation></Reference><Reference><Citation>Neustaeter B. Regions in Alberta, Manitoba Reporting Lowest Vaccination Rates across Canada.  [(accessed on 29 May 2024)].  Available online:  https://www.ctvnews.ca/health/coronavirus/regions-in-alberta-manitoba-reporting-lowest-vaccination-rates-across-canada-1.5541605.</Citation></Reference><Reference><Citation>Sugiyama A., Kurisu A., Nagashima S., Hando K., Saipova K., Akhmedova S., Abe K., Imada H., Hussain M.R.A., Ouoba S., et al. Seroepidemiological Study of Factors Affecting Anti-Spike IgG Antibody Titers after a Two-Dose mRNA COVID-19 Vaccination in 3744 Healthy Japanese Volunteers. Sci. Rep. 2022;12:16294. doi: 10.1038/s41598-022-20747-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-20747-x</ArticleId><ArticleId IdType="pmc">PMC9520958</ArticleId><ArticleId IdType="pubmed">36175506</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pérez-Alós L., Armenteros J.J.A., Madsen J.R., Hansen C.B., Jarlhelt I., Hamm S.R., Heftdal L.D., Pries-Heje M.M., Møller D.L., Fogh K., et al. Modeling of Waning Immunity after SARS-CoV-2 Vaccination and Influencing Factors. Nat. Commun. 2022;13:1614. doi: 10.1038/s41467-022-29225-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29225-4</ArticleId><ArticleId IdType="pmc">PMC8960902</ArticleId><ArticleId IdType="pubmed">35347129</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards N.E., Keshavarz B., Workman L.J., Nelson M.R., Platts-Mills T.A.E., Wilson J.M. Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine. JAMA Netw. Open. 2021;4:e2124331. doi: 10.1001/jamanetworkopen.2021.24331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.24331</ArticleId><ArticleId IdType="pmc">PMC8414189</ArticleId><ArticleId IdType="pubmed">34473262</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox L.S., Bellantuono I., Lord J.M., Sapey E., Mannick J.B., Partridge L., Gordon A.L., Steves C.J., Witham M.D. Tackling Immunosenescence to Improve COVID-19 Outcomes and Vaccine Response in Older Adults. Lancet Healthy Longev. 2020;1:e55–e57. doi: 10.1016/S2666-7568(20)30011-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(20)30011-8</ArticleId><ArticleId IdType="pmc">PMC7834195</ArticleId><ArticleId IdType="pubmed">33521768</ArticleId></ArticleIdList></Reference><Reference><Citation>Velásquez García H.A., Wilton J., Smolina K., Chong M., Rasali D., Otterstatter M., Rose C., Prystajecky N., David S., Galanis E., et al. Mental Health and Substance Use Associated with Hospitalization among People with COVID-19: A Population-Based Cohort Study. Viruses. 2021;13:2196. doi: 10.3390/v13112196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112196</ArticleId><ArticleId IdType="pmc">PMC8624346</ArticleId><ArticleId IdType="pubmed">34835002</ArticleId></ArticleIdList></Reference><Reference><Citation>Skorupa M., Szczepanek J., Goroncy A., Jarkiewicz-Tretyn J., Ptaszyńska B., Rajewski P., Koper W., Pałgan K., Tretyn A. The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines. Vaccines. 2022;10:506. doi: 10.3390/vaccines10040506.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10040506</ArticleId><ArticleId IdType="pmc">PMC9024925</ArticleId><ArticleId IdType="pubmed">35455255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeulin H., Labat C., Duarte K., Toupance S., Nadin G., Craus D., Georgiopoulos I., Gantois I., Goehringer F., Benetos A. Anti-Spike IgG Antibody Kinetics Following the Second and Third Doses of BNT162b2 Vaccine in Nursing Home Residents. J. Am. Geriatr. Soc. 2022;70:2552–2560. doi: 10.1111/jgs.17837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.17837</ArticleId><ArticleId IdType="pmc">PMC9115082</ArticleId><ArticleId IdType="pubmed">35484977</ArticleId></ArticleIdList></Reference><Reference><Citation>Mubarak A., Almutairi S., Al-Dhabbah A.D., Aldabas S.Y., Bhat R., Alqoufail M.M., Abdel-Maksoud M.A., Almanaa T.N., Farrag M.A., Alturaiki W. Durability of SARS-CoV-2 Specific IgG Antibody Responses Following Two Doses of Match and Mixed COVID-19 Vaccines Regimens in Saudi Population. Infect. Drug Resist. 2022;15:3791–3800. doi: 10.2147/IDR.S369769.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S369769</ArticleId><ArticleId IdType="pmc">PMC9296867</ArticleId><ArticleId IdType="pubmed">35875613</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., May A., Polidori L., Louca P., Wolf J., Capdevila J., Hu C., Ourselin S., Steves C.J., Valdes A.M., et al. COVID-19 Vaccine Waning and Effectiveness and Side-Effects of Boosters: A Prospective Community Study from the ZOE COVID Study. Lancet Infect. Dis. 2022;22:1002–1010. doi: 10.1016/S1473-3099(22)00146-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00146-3</ArticleId><ArticleId IdType="pmc">PMC8993156</ArticleId><ArticleId IdType="pubmed">35405090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapuente D., Winkler T.H., Tenbusch M. B-Cell and Antibody Responses to SARS-CoV-2: Infection, Vaccination, and Hybrid Immunity. Cell. Mol. Immunol. 2024;21:144–158. doi: 10.1038/s41423-023-01095-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01095-w</ArticleId><ArticleId IdType="pmc">PMC10805925</ArticleId><ArticleId IdType="pubmed">37945737</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A.S., Jones F.K., Nodoushani A., Kelly M., Becker M., Slater D., Mills R., Teng E., Kamruzzaman M., Garcia-Beltran W.F., et al. Persistence and Decay of Human Antibody Responses to the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 Patients. Sci. Immunol. 2020;5:eabe0367. doi: 10.1126/sciimmunol.abe0367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe0367</ArticleId><ArticleId IdType="pmc">PMC7857394</ArticleId><ArticleId IdType="pubmed">33033172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley G.E., Edwards E.S.J., Aui P.M., Varese N., Stojanovic S., McMahon J., Peleg A.Y., Boo I., Drummer H.E., Hogarth P.M., et al. Rapid Generation of Durable B Cell Memory to SARS-CoV-2 Spike and Nucleocapsid Proteins in COVID-19 and Convalescence. Sci. Immunol. 2020;5:eabf8891. doi: 10.1126/sciimmunol.abf8891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf8891</ArticleId><ArticleId IdType="pmc">PMC7877496</ArticleId><ArticleId IdType="pubmed">33443036</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.S., Kim W., Kalaidina E., Goss C.W., Rauseo A.M., Schmitz A.J., Hansen L., Haile A., Klebert M.K., Pusic I., et al. SARS-CoV-2 Infection Induces Long-Lived Bone Marrow Plasma Cells in Humans. Nature. 2021;595:421–425. doi: 10.1038/s41586-021-03647-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03647-4</ArticleId><ArticleId IdType="pubmed">34030176</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O’Brien K.L., Smith P.G., et al. Duration of Effectiveness of Vaccines against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression. Lancet Lond. Engl. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz B., Richards N.E., Workman L.J., Patel J., Muehling L.M., Canderan G., Murphy D.D., Brovero S.G., Ailsworth S.M., Eschenbacher W.H., et al. Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Front. Immunol. 2022;13:850987. doi: 10.3389/fimmu.2022.850987.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.850987</ArticleId><ArticleId IdType="pmc">PMC8978955</ArticleId><ArticleId IdType="pubmed">35386716</ArticleId></ArticleIdList></Reference><Reference><Citation>Self W.H., Tenforde M.W., Rhoads J.P., Gaglani M., Ginde A.A., Douin D.J., Olson S.M., Talbot H.K., Casey J.D., Mohr N.M., et al. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson &amp; Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions—United States, March–August 2021. MMWR Morb. Mortal. Wkly. Rep. 2021;70:1337–1343. doi: 10.15585/mmwr.mm7038e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7038e1</ArticleId><ArticleId IdType="pmc">PMC8459899</ArticleId><ArticleId IdType="pubmed">34555004</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health Agency of Canada COVID-19 Vaccines: Canadian Immunization Guide.  [(accessed on 16 January 2024)].  Available online:  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html.</Citation></Reference><Reference><Citation>Vinh D.C., Gouin J.-P., Cruz-Santiago D., Canac-Marquis M., Bernier S., Bobeuf F., Sengupta A., Brassard J.-P., Guerra A., Dziarmaga R., et al. Real-World Serological Responses to Extended-Interval and Heterologous COVID-19 mRNA Vaccination in Frail, Older People (UNCoVER): An Interim Report from a Prospective Observational Cohort Study. Lancet Healthy Longev. 2022;3:e166–e175. doi: 10.1016/S2666-7568(22)00012-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00012-5</ArticleId><ArticleId IdType="pmc">PMC8863504</ArticleId><ArticleId IdType="pubmed">35224524</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvin C., Retnakumar S.V., Bayry J. Obesity Negatively Impacts Maintenance of Antibody Response to COVID-19 Vaccines. Cell Rep. Med. 2023;4:101117. doi: 10.1016/j.xcrm.2023.101117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101117</ArticleId><ArticleId IdType="pmc">PMC10394250</ArticleId><ArticleId IdType="pubmed">37467723</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M.Z., Sng J.D., Carney M., Cooper L., Brown S., Lineburg K.E., Chew K.Y., Collins N., Ignacio K., Airey M., et al. Elevated BMI Reduces the Humoral Response to SARS-CoV-2 Infection. Clin. Transl. Immunol. 2023;12:e1476. doi: 10.1002/cti2.1476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1476</ArticleId><ArticleId IdType="pmc">PMC10693902</ArticleId><ArticleId IdType="pubmed">38050635</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>